Open access · CC-BY
via OpenAlex
The PI3K-Akt-mTOR and Associated Signaling Pathways as Molecular Drivers of Immune-Mediated Inflammatory Skin Diseases: Update on Therapeutic Strategy Using Natural and Synthetic Compounds
Tithi Roy, Samuel T. Boateng, Mohammad B. Uddin, Sergette Banang‐Mbeumi, Rajesh Kumar Yadav, Chelsea R. Bock, Joy T. Folahan, Xavier Siwe‐Noundou, Anthony L. Walker, Judy A. C. King, Claudia Buerger, Shile Huang, Jean Christopher Chamcheu
Cells · 2023 · ▲ 161 citations
Deregulated nutrient-sensing
Altered intercellular communication
Chronic inflammation
Rapamycin / mTOR inhibition
Human
Review
Abstract
The dysregulated phosphatidylinositol-3-kinase (PI3K)-Akt-mammalian target of mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">rapamycin(definition) (mTOR) signaling pathway has been implicated in various immune-mediated inflammatory and hyperproliferative dermatoses such as acne, atopic dermatitis, alopecia, psoriasis, wounds, and vitiligo, and is associated with poor treatment outcomes. Improved comprehension of the consequences of the dysregulated PI3K/Akt/mTOR pathway in patients with inflammatory dermatoses has resulted in the development of novel therapeutic approaches. Nonetheless, more studies are necessary to validate the regulatory role of this pathway and to create more effective preventive and treatment methods for a wide range of inflammatory skin diseases. Several studies have revealed that certain natural products and synthetic compounds can obstruct the expression/activity of PI3K/Akt/mTOR, underscoring their potential in managing common and persistent skin inflammatory disorders. This review summarizes recent advances in understanding the role of the activated PI3K/Akt/mTOR pathway and associated components in immune-mediated inflammatory dermatoses and discusses the potential of bioactive natural products, synthetic scaffolds, and biologic agents in their prevention and treatment. However, further research is necessary to validate the regulatory role of this pathway and develop more effective therapies for inflammatory skin disorders.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.3390/cells12121671
- Canonical
- link ↗
- Fetched
- 2026-09-29 MST
Cite this
APA
Roy, T., Boateng, S.T., Uddin, M.B., Banang‐Mbeumi, S., Yadav, R.K., Bock, C.R., Folahan, J.T., Siwe‐Noundou, X., Walker, A.L., King, J.A.C., Buerger, C., Huang, S., & Chamcheu, J.C. (2023). The PI3K-Akt-mTOR and Associated Signaling Pathways as Molecular Drivers of Immune-Mediated Inflammatory Skin Diseases: Update on Therapeutic Strategy Using Natural and Synthetic Compounds. <em>Cells</em>. https://doi.org/10.3390/cells12121671
Vancouver
Roy T, Boateng ST, Uddin MB, Banang‐Mbeumi S, Yadav RK, Bock CR, et al. The PI3K-Akt-mTOR and Associated Signaling Pathways as Molecular Drivers of Immune-Mediated Inflammatory Skin Diseases: Update on Therapeutic Strategy Using Natural and Synthetic Compounds. Cells. 2023. doi:10.3390/cells12121671.
BibTeX
@article{tithi2023ThePIK,
title = {The PI3K-Akt-mTOR and Associated Signaling Pathways as Molecular Drivers of Immune-Mediated Inflammatory Skin Diseases: Update on Therapeutic Strategy Using Natural and Synthetic Compounds},
author = {Tithi Roy and Samuel T. Boateng and Mohammad B. Uddin and Sergette Banang‐Mbeumi and Rajesh Kumar Yadav and Chelsea R. Bock and Joy T. Folahan and Xavier Siwe‐Noundou and Anthony L. Walker and Judy A. C. King and Claudia Buerger and Shile Huang and Jean Christopher Chamcheu},
journal = {Cells},
year = {2023},
doi = {10.3390/cells12121671},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Journal of Clinical Medicine 2020
Open access · CC-BY
Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence
Molecular Cancer 2023
Open access · CC-BY
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Aging Pathobiology and Therapeutics 2026
Open access · CC-BY
mTOR signaling in aging and longevity: therapeutic opportunities
Therapeutic Advances in Medical Oncology 2024
Open access · CC-BY
Inhibition of the PI3K/AKT/mTOR pathway in pancreatic cancer: is it a worthwhile endeavor?
Cells 2019
Open access · CC-BY
Role and Therapeutic Targeting of the PI3K/Akt/mTOR Signaling Pathway in Skin Cancer: A Review of Current Status and Future Trends on Natural and Synthetic Agents Therapy
PubMed 2010
Preprint